A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

Abstract Background Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms. Methods Study design: COMBIVAS is a randomised, double-blind, placebo-controlled...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Mark E. McClure, Seerapani Gopaluni, James Wason, Robert B. Henderson, Andre Van Maurik, Caroline C.O. Savage, Charles D. Pusey, Alan D. Salama, Paul A. Lyons, Jacinta Lee, Kim Mynard, David R. Jayne, Rachel B. Jones, on behalf the COMBIVAS investigators
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2023-03-01
Schriftenreihe:	Trials
Schlagworte:	ANCA Vasculitis Rituximab Belimumab
Online-Zugang:	https://doi.org/10.1186/s13063-023-07218-y
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!